India, May 20 -- image credit- freepik

Ichnos Glenmark Innovation, Inc. (IGI), Mumbai-based Glenmark Pharma's innovation arm, has announced a new development candidate, ISB 2301, a first-in-class, multispecific immune cells (T and NK) activator, for the potential treatment of multiple solid tumour indications.

ISB 2301 targets three tumour-associated antigens to trigger tumor cell death and engages both T cells and NK cells to ignite the immune system.

IGI designed ISB 2301 to induce potent antibody-dependent cellular cytotoxicity (ADCC), potent checkpoint inhibition, and a sustained type 1 immune response. IGI's proprietary BEAT(R) technology enabled the development of this next-generation multispecific antibody, which can be manufact...